Ocular Therapeutix Inc (NASDAQ:OCUL) Short Interest Update

Ocular Therapeutix Inc (NASDAQ:OCUL) saw a significant growth in short interest in November. As of November 29th, there was short interest totalling 6,880,000 shares, a growth of 6.5% from the November 14th total of 6,460,000 shares. Based on an average trading volume of 524,600 shares, the short-interest ratio is presently 13.1 days. Approximately 16.6% of the company’s stock are short sold.

OCUL stock traded up $0.01 during trading hours on Friday, hitting $4.06. The company’s stock had a trading volume of 319,141 shares, compared to its average volume of 638,003. The company has a debt-to-equity ratio of 5.07, a quick ratio of 6.25 and a current ratio of 6.33. Ocular Therapeutix has a 12 month low of $2.35 and a 12 month high of $5.64. The stock has a 50 day moving average price of $3.45 and a two-hundred day moving average price of $3.93.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.01. The company had revenue of $0.83 million during the quarter, compared to the consensus estimate of $1.09 million. Ocular Therapeutix had a negative net margin of 3,141.58% and a negative return on equity of 383.58%. As a group, equities analysts anticipate that Ocular Therapeutix will post -1.72 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in shares of Ocular Therapeutix during the 3rd quarter worth $31,000. SG Americas Securities LLC bought a new stake in shares of Ocular Therapeutix during the 3rd quarter worth $32,000. Creative Planning bought a new stake in shares of Ocular Therapeutix during the 2nd quarter worth $52,000. Clear Harbor Asset Management LLC bought a new stake in shares of Ocular Therapeutix during the 3rd quarter worth $38,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Ocular Therapeutix during the 3rd quarter worth $44,000. 48.01% of the stock is owned by institutional investors.

Several analysts have commented on the stock. Piper Jaffray Companies decreased their target price on shares of Ocular Therapeutix from $8.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $6.00 target price (down from $9.00) on shares of Ocular Therapeutix in a research report on Friday, November 15th. Finally, Zacks Investment Research raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Friday, November 15th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Ocular Therapeutix currently has a consensus rating of “Buy” and a consensus price target of $8.67.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Further Reading: Inverted Yield Curve

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.